Tvardi Therapeutics

Yahoo Finance • 4 months ago

SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or o... Full story

Yahoo Finance • 4 months ago

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or o... Full story

Yahoo Finance • 5 months ago

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or o... Full story

Yahoo Finance • 5 months ago

Tvardi Therapeutics GAAP EPS of -$0.59 beats by $0.22

* Tvardi Therapeutics press release [https://seekingalpha.com/pr/20307239-tvardi-therapeutics-announces-third-quarter-2025-results-and-provides-business-update] (TVRD [https://seekingalpha.com/symbol/TVRD]): Q3 GAAP EPS of -$0.59 beats b... Full story

Yahoo Finance • 5 months ago

TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (“Tvardi” or “the Company”)... Full story

Yahoo Finance • 5 months ago

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or o... Full story

Yahoo Finance • 6 months ago

Tivardi downgraded at Raymond James following TTI-101 trial failure

[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov * Raymond James downgraded Tivardi Therapeutics (NASDAQ:TVRD [https://seekingalpha.com/symbol/TVRD]) to market perform from outperform citing the recent disappointi... Full story

Yahoo Finance • 6 months ago

Tivardi tanks on phase 2 data of TTI-101 in idiopathic pulmonary fibrosis

[Red down arrow on a white tiled wall. Illustration of the concept of financial crisis, recession and economic turmoil] Dragon Claws Tivardi Therapeutics (NASDAQ:TVRD [https://seekingalpha.com/symbol/TVRD]) is down ~85% in Monday trading... Full story

Yahoo Finance • 6 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 9 months ago

Tvardi Therapeutics director Shaheen Wirk resigns from board

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) announced Monday that Shaheen Wirk resigned from its board of directors on July 8. According to a statement from the company, Dr. Wirk’s decision to step down was not the result of any disagreement w... Full story

Yahoo Finance • 9 months ago

Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating

Investing.com - Cantor Fitzgerald initiated coverage on Tvardi Therapeutics Inc (NASDAQ:TVRD) with an Overweight rating and a price target of $52.00 on Friday. The $212 million market cap company currently trades at $22.67, with analysts s... Full story

Yahoo Finance • 11 months ago

Tvardi Therapeutics files to sell 2.08M shares of common stock for holders

* Tvardi Therapeutics (NASDAQ:TVRD [https://seekingalpha.com/symbol/TVRD]) files to sell 2.08M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10046911] MORE ON TVARDI THERAPEUTICS * Historical earning... Full story